Heartseed, Inc. (JP:219A)
:219A
Want to see JP:219A full AI Analyst Report?
219A Stock Chart & Stats
¥1804.00
-¥95.00(-2.73%)
At close: 4:00 PM EST
¥1804.00
-¥95.00(-2.73%)
Day’s Range― - ―
52-Week Range¥1,343.00 - ¥4,385.00
Previous CloseN/A
Volume1.41M
Average Volume (3M)738.74K
Market Cap
¥36.80B
Enterprise Value¥29.80B
Total Cash (Recent Filing)¥7.34B
Total Debt (Recent Filing)¥890.00K
Price to Earnings (P/E)―
Beta1.19
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding22,874,200
10 Day Avg. Volume469,170
30 Day Avg. Volume738,736
Financial Highlights & Ratios
PEG Ratio-2.00
Price to Book (P/B)5.17
Price to Sales (P/S)12.93
P/FCF Ratio37.21
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative Balance Sheet / Low LeverageExtremely low leverage and a large equity base give durable financial flexibility for a biotech. This reduces bankruptcy risk, enables multi-year R&D funding, supports partnering or milestone-driven deal making, and cushions operations during clinical cycles without immediate capital raises.
Return To Profitability And Positive Cash FlowA sustained inflection to profitability and positive free cash flow materially strengthens long-term viability. If maintained, internally generated cash can fund continued clinical development, reduce dependence on dilutive financings, and improve negotiating leverage with partners.
Meaningful Revenue Growth And Healthy Margins In FY2025A material revenue increase combined with double-digit EBIT and net margins indicates product or licensing traction. Sustainable margins provide capacity to reinvest in R&D and commercialization, improving the company’s ability to scale therapies and sustain long-term value creation.
Bears Say
Multi-year Losses And Historical Cash BurnSeveral years of heavy losses and cash burn underscore execution and funding risk. Biotech development can revert to negative cash flow if trials set back; historical volatility means future profitability is not guaranteed and could force dilutive raises or partnership compromises.
Inconsistent Gross Profit ReportingIrregular gross profit disclosures impair assessment of core unit economics and long-term margin sustainability. Without consistent gross-margin metrics, forecasting cost of goods, pricing power, and scalability of therapies is harder, raising execution and modeling uncertainty.
Small Organizational ScaleA very small headcount limits internal capacity to run multiple clinical programs, regulatory submissions, and commercialization efforts simultaneously. Long-term scaling often requires partnerships or hiring, which increases cost and execution complexity during critical growth phases.
Heartseed, Inc. News
219A FAQ
What was Heartseed, Inc.’s price range in the past 12 months?
Heartseed, Inc. lowest stock price was ¥1343.00 and its highest was ¥4385.00 in the past 12 months.
What is Heartseed, Inc.’s market cap?
Heartseed, Inc.’s market cap is ¥36.80B.
When is Heartseed, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Heartseed, Inc.’s earnings last quarter?
Currently, no data Available
Is Heartseed, Inc. overvalued?
According to Wall Street analysts Heartseed, Inc.’s price is currently Overvalued.
Does Heartseed, Inc. pay dividends?
Heartseed, Inc. does not currently pay dividends.
What is Heartseed, Inc.’s EPS estimate?
Heartseed, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Heartseed, Inc. have?
Heartseed, Inc. has 22,874,200 shares outstanding.
What happened to Heartseed, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Heartseed, Inc.?
Currently, no hedge funds are holding shares in JP:219A
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Heartseed, Inc.
Heartseed, Inc. engages in the provision of cardiac regenerative medicine. The company was founded by Keiichi Fukuda, Takumi Akiyama, Toshiharu Furukawa and Yutaro Kasai on November 30, 2015 and is headquartered in Tokyo, Japan.
Technical Analysis
Pharmarise Holdings Corp.
―
COSMOS Pharmaceutical Corporation
―
Medical System Network Co., Ltd.
―
Shinnihonseiyaku Co., Ltd.
―
Chordia Therapeutics Inc.
―